The transmission blocking activity of artemisinin-combination, non-artemisinin, and 8-aminoquinoline antimalarial therapies: a pooled analysis of individual participant data.

Leen N Vanheer, MD[1]*, Jordache Ramjith, PhD[2]*, Almahamoudou Mahamar, PhD[3]*, Merel J Smit, MD[2], Kjerstin Lanke[2], Michelle E Roh, PhD[4], Koualy Sanogo, MD[3], Youssouf Sinaba, MD[3], Sidi M. Niambele, PharmD[3], Makonon Diallo, MD[3], Seydina O Maguiraga, MD[3], Sekouba Keita, MS[3], Siaka Samake, PharmD[3], Ahamadou Youssouf PharmD[3], Halimatou Diawara, MD[3], Sekou F. Traore, PhD[3], Roly Gosling, MD[5,6], Joelle M Brown, PhD[6], Chris Drakeley, PhD[1], Alassane Dicko, MD[3†], Will Stone, PhD[1†], Teun Bousema, PhD[2†]

[1]Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK, WC1E7HT

[2]Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands

[3]Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali

[4]Institute for Global Health Sciences, University of California, San Francisco, CA, USA.

[5]Department of Disease Control, London School of Hygiene and Tropical Medicine, London UK.

[6]Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.

* Joint first authors, contributed equally

† Joint last authors, contributed equally

Corresponding author: Teun Bousema: teun.bousema@radboudumc.nl

Abbreviations

ACT, artemisinin-based combination therapy; AL, Artemether-lumefantrine; AL-AQ; Artemether-lumefantrine-amodiaquine; AQ, Amodiaquine; AS-AQ, Artesunate-Amodiaquine; DHA-PPQ, Dihydroartemisinin-Piperaquine; G6PD; glucose-6-phosphate dehydrogenase; PY-AS, Pyronaridine-Artesunate; PQ, Primaquine; SLD, Single low-dose; RT-qPCR, reverse-transcriptase quantitative PCR; SP-AQ, Sulfadoxine-pyrimethamine plus Amodiaquine; TACT, Triple artemisinin-based combination therapy; TQ, Tafenoquine; WHO, World Health Organisation.

ABSTRACT

Background: Interrupting human-to-mosquito transmission is important for malaria elimination strategies as it can reduce infection burden in communities and slow the spread of drug resistance. Antimalarial medications differ in their efficacy in clearing the transmission stages of *Plasmodium falciparum* (gametocytes) and in preventing mosquito infection. Here we present a combined analysis of six trials conducted at the same study site with highly consistent methodologies that allows for a direct comparison of the gametocytocidal and transmission-blocking activities of fifteen different antimalarial regimens or dosing schedules.

Methods and findings: Between January 2013 and January 2023, six clinical trials with transmission endpoints were conducted at the Clinical Research Centre of the Malaria Research and Training Centre of the University of Bamako in Mali. These trials tested Artemisinin-Combination Therapies (ACTs), non-ACT regimens and combinations with 8-aminoquinolines. Participants were males and non-pregnant females, between 5-50 years of age, who presented with *P. falciparum* mono-infection and gametocyte carriage by microscopy. Blood samples were taken before and after treatment for thick film microscopy, infectivity assessments by mosquito feeding assays and molecular quantification of gametocytes. Mixed-effects generalized linear models were fit with individual-specific random effects and fixed effects for time points, treatment groups and their interaction. Models quantified changes in mosquito infection rates and gametocyte densities within treatment arms over time and between treatments. In a pooled analysis of 422 participants, we observed substantial differences between ACTs in gametocytocidal and transmission-blocking activities, with artemether-lumefantrine (AL) being significantly more potent at reducing mosquito infection rates within 48 hours than dihydroartemisinin-piperaquine (DHA-PPQ), artesunate-amodiaquine (AS-AQ) and pyronaridine-artesunate (PY-AS) ($p < 0.0001$). The addition of single low dose primaquine (SLD PQ) accelerated gametocyte clearance and led to a

significantly greater reduction in mosquito infection rate within 48-hours of treatment for each ACT, while an SLD of the 8-aminoaquinoline tafenoquine (TQ) showed a delayed but effective response compared to SLD primaquine. Finally, our findings confirmed considerably higher post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ) compared to most ACTs, with a significantly lower relative reduction in mosquito infection rate at day 7 compared to DHA-PPQ, AS-AQ, and AL ($p<0.0001$). Therefore, adding an SLD PQ to SP-AQ may be beneficial to block malaria transmission in community treatment campaigns.

Conclusions: We found marked differences among ACTs and single low-dose 8-aminoquinoline drugs in their ability and speed to block transmission. The findings from this analysis can support treatment policy decisions for malaria elimination and be integrated into mathematical models to improve the accuracy of predictions regarding community transmission and the spread of drug resistance under varying treatment guidelines.

INTRODUCTION

The primary aim in the therapeutic management of malaria is the clearance of pathogenic asexual blood-stage parasites, using antimalarials with schizonticidal properties. Artemisinin-based combination therapies (ACTs) are the first-line treatment for uncomplicated *Plasmodium falciparum* malaria across the world and are highly potent against asexual parasites, capable of reducing the circulating asexual parasite biomass ~10,000 fold per 48 hour cycle (1). Gametocytes are distinct parasite stages that are not associated with symptoms but are the only parasite life stage that can be transmitted to and establish infection in mosquitoes. In *P. falciparum*, gametocytes develop during five developmental stages over a prolonged 10–12-day maturation period. Importantly, *P. falciparum* gametocytes have markedly different sensitivity profiles to antimalarial drugs than asexual parasites. Assessing and comparing the gametocytocidal and transmission-blocking properties of different antimalarial regimens is important for informing treatment guidelines that aim to contribute to transmission reduction.

Artemisinins are active against developing gametocytes but less so against the mature forms (2). Although gametocyte density generally decreases more after treatment with ACTs compared to non-ACTs (3), there is considerable variation in gametocyte-clearing potential between ACTs (4). For example, current artemisinin partner drugs such as piperaquine, lumefantrine and amodiaquine have limited activity against *P. falciparum* gametocytes at clinically relevant concentrations (2,5–7). *In vitro* data for the partner drug pyronaridine are contradictory; one study found a strong effect against mature gametocytes (8), whereas others only observed activity against mature gametocytes at concentrations above the therapeutic threshold (2,6,9). Furthermore, a disconnect exists between the detection of gametocytes and infectivity to mosquitoes; on the one hand, gametocytes can be infectious at sub-microscopic densities (10), whereas on the other, antimalarials can have a parasite-inhibiting effect, active

after ingestion by mosquitoes (2,11) or sterilise gametocytes so that these are detectable but not transmissible (12). Gametocyte quantification is therefore an imperfect measure of post-treatment transmission potential, and mosquito feeding assays are considered more informative (13).

With the threat of artemisinin partial resistance in sub-Saharan Africa (14), various strategies have been proposed to counter the spread of resistant parasites. One of the most promising approaches, according to modelling simulations, is the use of Triple Artemisinin-based Combination Therapies (TACT), that combine existing ACTs with a second partner drug. This approach may offer protection against partner drug resistance and maintain high treatment efficacy in areas where resistance against artemisinins and one of the partner drugs is present (15). Other suggested strategies include multiple first-line ACT therapies or cycling between different ACTs (16,17). An alternative or complementary strategy is to supplement treatment with gametocytocidal compounds. Primaquine (PQ) and its long-lasting analogue tafenoquine (TQ) are 8-aminoquinolines that can clear *P. vivax* liver stages (18) and have *P. falciparum* gametocytocidal activity. The WHO recommends supplementing first-line ACTs with a single low-dose (0.25mg/kg) PQ (SLD PQ) in low transmission areas (19), and the WHO malaria policy and advisory group has now suggested expanding this recommendation to other regions (20). TQ holds the promise of long-lasting transmission blocking activity and recently a single-low dose of TQ (SLD TQ) in combination with ACTs and non-ACT treatments was found to effectively block transmission within 7 days at a dose of 1.66 mg/kg (21,22). To date, no trials directly comparing SLD TQ to SLD PQ have been conducted, largely due to the impracticality of trials involving mosquito feeding assays.

In order to make informed decisions regarding optimal antimalarial regimens, it is necessary to understand and compare the transmission-blocking abilities of different ACTs and TACTs.

We conducted a pooled analysis of individual-level data from six clinical trials to compare the transmission-blocking effects of 15 different antimalarials and combinations. All six trials measured mosquito transmission endpoints, used sensitive gametocyte quantification, and were conducted using the same mosquito feeding protocols and assays in Ouélessébougou, Mali, between 2013 and 2023 (21–26). Results from this analysis can be used in mathematical models to more accurately predict community transmission and the spread of drug resistance under different treatment guidelines, and will inform malaria control programmes.

METHODS

Study design and participants

Between January 2013 and January 2023, six clinical trials (21–26) (Table 1) (appendix 2) involving a total of 521 participants were performed at the Clinical Research Centre of the Malaria Research and Training Centre (MRTC) of the University of Bamako (Bamako, Mali). Study participants were recruited in the commune of Ouélessébougou, which includes the central town of Ouélessébougou and 44 surrounding villages, with an estimated 50,000 inhabitants and located approximately 80 km south of Bamako, the capital of Mali. Malaria transmission in this region is hyperendemic and highly seasonal with incidence peaking during and following the rainy season from July to November. In all six trials, participants were males and non-pregnant females, between 5-50 years of age, with a body weight less than 80 kg, who presented with *P. falciparum* mono-infection and at least 1 (study acronyms PQ03, NECTAR 1-4) or 2 (study PQ01) gametocytes per 500 white blood cells (WBC) detected by blood smear. This minimum gametocyte density corresponds to an approximate minimum of 16-32 gametocytes per µL of blood when assuming 8000 WBC per µL. Participants in all studies, except for the 2013-2014 PQ01 study, were exclusively asymptomatic, and four studies (study acronyms PQ01, PQ03, NECTAR2, NECTAR3) required participants to have normal glucose-6-phosphate dehydrogenase (G6PD) production, as determined by OSMMR-D-D calorimetric test (R&D Diagnostics, Aghia Paraskevi, Greece; studies PQ01, NECTAR2 and NECTAR3), CareStart G6PD rapid diagnostic test (Access Bio, Somerset, NJ,USA; study PQ03) and/or STANDARD G6PD quantitative enzyme activity test (SD Biosensor, Suwon, South Korea; studies NECTAR2 and NECTAR3; table 1, appendix 2). Other study-specific inclusion criteria are presented in appendix 2.

Ethical approvals for the individual studies were obtained from the Ethics Committee of the

Faculty of Medicine, Pharmacy, and Dentistry of the University of Science, Techniques, and

Technologies of Bamako (Bamako, Mali). In addition, the studies were approved by the

Committee on Human Research at the University of California (San Francisco, CA, USA),

and/or the Research Ethics Committee of the London School of Hygiene and Tropical Medicine

(London, UK).

Procedures

Of the antimalarial treatments evaluated in the included studies, the following were included

in this analysis: i) Dihydroartemisinin-piperaquine (DHA-PPQ; Eurartesim; Sigma Tau,

Gaithersburg, MD, USA); ii) Pyronaridine-artesunate (PY-AS; Pyramax; Shin Poong

Pharmaceutical, Seoul, South Korea; iii) Artemether-lumefantrine (AL; Coartem; Novartis,

Basel, Switzerland or Guilin Pharmaceutical, Shanghai, China); iv) Artesunate-amodiaquine

(AS-AQ; Guilin Pharmaceutical, Shanghai, China); v) Sulfadoxine-pyrimethamine plus

amodiaquine (SP-AQ; Guilin Pharmaceutical, Shanghai, China); vi) Any of the ACTs listed

above plus a single low-dose of primaquine (ACT-PQ; 0.25 or 0.5 mg/kg; Sanofi, Laval, QC,

Canada or ACE Pharmaceuticals, Zeewolde, the Netherlands); vii) Non-ACT (SP-AQ) plus a

single low-dose of primaquine (Non-ACT-PQ; Sanofi, Laval, QC, Canada); viii) ACT (DHA-

PPQ) plus a single low dose of tafenoquine (ACT-TQ; 0.83 or 1.66 mg/kg; 60° Pharmaceuticals

Ltd, USA) (Table 1). Antimalarial treatments were administered as per manufacturer's

instructions (supplementary Information 1 for dosing tables and supplementary Table 1 for

manufacturers, appendix 1, pp 3-6) under direct supervision. ACT treatments and sulfadoxine-

pyrimethamine plus amodiaquine were administered over 3 days (days 0, 1, and 2). Primaquine

and tafenoquine were administered as a single dose immediately after the first dose of ACT. In

the NECTAR1 study, participants were treated with a full course of DHA-PPQ at day 21 of

follow-up, to prevent re-infection. For the current analysis, we did not consider study arms

within the included studies that are currently not considered as treatment regimens, such as

arms with PQ doses below 0.25 mg/kg (n=33 participants) and with TQ doses below 0.83

mg/kg (n=20). Likewise, treatment arms involving methylene blue (n=20) or the combination

of SP-AQ with an SLD TQ (n=20) were not considered in the analysis.

In all studies, blood samples were taken before treatment and on days 2 and 7 following

treatment for thick film microscopy, infectivity assessments and molecular analysis of

gametocyte density, as outlined in Figure 1 and described in detail in appendix 2.

For infectivity assessments in all studies, 75-90 insectary-reared *Anopheles gambiae* females

were allowed to feed for 15–20 min on venous blood samples collected in Lithium Heparin

tubes and offered in a water-jacketed membrane feeder system, as previously described (27).

Fully fed mosquitoes were kept in a temperature and humidity-controlled insectary until day 7

post-feeding, and then dissected in 1% mercurochrome to detect and quantify *P. falciparum*

oocysts. Giemsa-stained blood slides were double read by expert research microscopists with

asexual stages counted against 200 white blood cells and gametocytes counted against 500

white blood cells. For molecular gametocyte quantification in all studies, venous or finger-

prick blood collected in EDTA tubes was aliquoted into L6 buffer (Severn Biotech,

Kidderminster, UK) or RNA protect cell reagent (Qiagen, Hilden, Germany) and stored at

$\leq -70°C$ until total nucleic acid extraction using a MagNAPure LC automated extractor (Total

Nucleic Acid Isolation Kit High Performance; Roche Applied Science, Indianapolis, IN, USA).

Male and female gametocytes were quantified in a multiplex reverse-transcriptase quantitative

PCR (RT-qPCR) assay targeting Pfs25 or CCP4 transcripts for female gametocytes and

PfMGET for male gametocyte quantification, as specified in appendix 2. Molecular

gametocyte quantification was repeated for the PQ03 study, after the original density estimates

of this study (but not of other studies) showed marked disagreement with their respective

microscopy density measurements (supplementary figure 1, appendix 1, p 7). Samples were

classified as negative for a specific gametocyte sex if the RT-qPCR quantified gametocyte

density was less than 0.01 gametocytes per μL (equivalent to one gametocyte per 100 μL of

the blood sample).

Statistical analysis

Asexual parasite and microscopy gametocyte density distributions at baseline were presented

per study by violin plots. Six individuals from the PQ01 study that lacked baseline infectivity

measures or microscopy gametocyte densities were excluded from analysis. The association

between gametocyte density (gametocytes / μL) on a log10 scale and the proportion of infected

mosquitoes was determined by a mixed-effects logistic regression with a random effect for

study. The association between (log10) gametocyte density estimates by microscopy and

molecular methods was determined by a linear model with an interaction by study.

To quantify reductions in key output parameters (gametocyte prevalence and densities, the

proportion of infected mosquitos, mean oocyst density) within treatments over time (days 2, 7

and 14) and between treatments at each time point, mixed-effects generalized linear models

were fit with individual-specific random effects and fixed effects for time points, treatment

groups and their interaction. A Poisson family with log-link was used for gametocyte

prevalence (since a binomial family with log-link failed to converge), a Gamma family with

log-link was used for gametocyte densities assessed by microscopy and RT-qPCR, a binomial

family with log-link was used for proportion of infected mosquitos, while a negative binomial

family with log-link was used for oocyst density.

The models were of the form:

221
$$y_i = \exp\left(\beta_0 + \sum_{k=1}^{8} \beta_{1k} \times arm_{ik} + \sum_{j=0}^{3} \beta_{2j} \times t_{ij} + \sum_{k=1}^{8}\sum_{j=0}^{3} \beta_{3kj} \times arm_{ik} \times t_{ij} + Z_i\right),$$

where the study arms were DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ

and ACT-TQ, and the time points were t_0=day 0, t_1=day 2, t_2=day 7 and t_3=day 14, the β's

are the regression parameters to be estimated, Z_i are the individual specific random effects, and

y_i is one of the outcomes of interest: gametocyte prevalence or densities, the proportion of

infected mosquitos, oocyst density. The beta (β) coefficients estimated from the model were

used to calculate the relative reductions at each time point for each treatment arm.

Kaplan-Meier survival curves were generated with the *survfit* function from the R-based

survival package to display the cumulative probability of remaining uncleared of gametocytes

detected by microscopy, gametocytes detected by RT-qPCR and any infectivity to mosquitoes.

The Cox proportional hazards model was used to estimate hazard ratios and to draw

comparisons between treatment arms for each of the clearance events. Statistical analyses and

visualisations were conducted in R (version 4.3.2).

The original studies were registered with ClinicalTrials.gov (NCT01743820, NCT02831023,

NCT04049916, NCT04609098, NCT05081089 and NCT05550909).

RESULTS

A total of 422 study participants (42-100 participants per study) and 15 different treatment regimens or dosing schedules were evaluated across the six included trials (20-79 participants per regimen/dosing schedule, Table 1, Appendix 2). Parasite density was broadly similar between studies that recruited asymptomatic parasite carriers (2016-2022) but higher in the PQ01 study conducted in 2013-2014 where clinical malaria patients were eligible (Figure 2A). Although participants were recruited based on microscopically detected gametocyte carriage, at the time of enrolment (up to 24 hours after the initial screening), microscopy gametocyte prevalence was 99.5% (420/422) with a median gametocyte density of 55 (IQR 32-112) gametocytes/µL among gametocyte carriers (Figure 2B). Gametocyte density by microscopy was highly skewed with a range of 15.5-2720 gametocytes/µL (supplementary table 2, appendix 1, p 8). Prior to treatment, 68.8% (290/422) of individuals were infectious to mosquitoes (Figure 2C). The proportion of mosquitoes each participant infected at this time point ranged from 0.75% to 94.3% and was positively associated with microscopically determined gametocyte density (Figure 2D). In the four studies where oocyst numbers were recorded (NECTAR studies 1-4), the proportion of mosquitoes infected was strongly positively associated with mosquito infection burden (oocyst density) (supplementary figure 2, appendix 1, p 9).

Acknowledging that densities below the microscopic threshold for detection (16 gametocytes/µL) can result in mosquito infections, gametocyte density was also quantified by molecular methods. For all studies, gametocyte prevalence by molecular methods was 100% at enrolment and there was a strong positive association between gametocyte density by microscopy and by molecular methods (Figure 3A). At enrolment, two study participants were positive for

gametocytes by molecular methods but not by microscopy; both became gametocyte positive

by microscopy one day after baseline.

Following treatment, gametocyte prevalence and densities declined in all treatment groups. The

extent and speed at which this occurred depended strongly on the treatment provided (Figure

3B-D, supplementary figure 3, appendix 1, p 10). Two days after treatment, relative reductions

compared to baseline in microscopically detected gametocyte prevalence were non-significant

in all arms. However, at seven days after treatment initiation, this reduction was statistically

significant in the AL group (51.12%, 95% CI 3.85% -75.15%, p=0.0381), but not after the

other schizonticidal regimens without addition of a gametocytocide (p=0.2258, p=0.3892,

p=0.5731 and p=0.7997 after DHA-PPQ, SP-AQ, PY-AS and AS-AQ treatment, respectively).

The reduction in gametocyte prevalence was more rapid for treatment groups that included a

single low-dose gametocytocide, with reductions of 68.31% (95% CI 10.02% -88.84%,

p=0.0309) in the non-ACT-PQ group, 90.52% (95% CI 78.52% -95.81%, p<0.0001) in the

ACT-PQ group and 61.53% (95% CI 16.07% -82.37%, p=0.0164) in the ACT-TQ group, at

day 7 compared to baseline. Relative reductions in gametocyte prevalence assessed by

microscopy and molecular methods at days 2, 7 and 14 post-treatment are presented in Figure

3B and supplementary tables 3-8 (appendix 1, pp 11-16). We combined different ACTs with

PQ for this analysis; the findings per study arm are given in supplementary figure 4 (appendix

1, p17).

Reductions in gametocyte prevalence were predictably slower than reductions in gametocyte

densities, which showed significant relative reductions at day 2 compared to baseline by both

microscopy and molecular measures in the AL (p=0.0116 and p<0.0001, respectively) and

ACT-PQ (p=0.0003 and p<0.0001, respectively) groups (Figure 3 C-D, supplementary tables

9-14, supplementary figure 5, appendix 1, pp 18-24). Reductions in PCR-determined

gametocyte density on day 2 after initiation of treatment were more pronounced for AL compared to DHA-PPQ (p=0.0036), SP-AQ (p=0.0308), PY-AS (p=0.0302) (supplementary table 12, appendix 1, p 21) with similar patterns at day 7 and 14 (supplementary tables 13 and 14, appendix 1, p 22-23). AS-AQ also resulted in a smaller reduction in gametocyte density compared to AL, which was not significant on day 2 (p=0.1085) but became significant at later timepoints (p=0.0617 and p=0.0013 at days 7 and 14). ACT-PQ resulted in the fastest reductions in molecular gametocyte density and this reduction was significantly larger than the best performing ACT, AL, on days 7 and 14 (p<0.0001; supplementary tables 13 and 14, appendix 1, pp 22-23). Non-ACT-PQ and ACT-TQ regimens showed reductions of nearly 30% in gametocyte density by PCR on day 2, which was significantly less than in the ACT-PQ group (p=0.0400 and p=0.0043, respectively). Across all post-treatment timepoints, the proportion of gametocyte infections that were submicroscopic was 28.63% (777/2714).

A valuable feature of the studies included was the availability of mosquito infection data before and after initiation of treatment. In all groups, 58.3% to 95% of participants infected mosquitoes before treatment (supplementary table 2, appendix 1, p 8), with 99.7% (289/290) of infectious individuals having gametocytes detected by microscopy at this timepoint. Following treatment, as gametocyte densities declined, the contribution of submicroscopic infections to transmission increased (Figure 4A). At day 2, 8.33% (12/144) of all infectious individuals had submicroscopic gametocyte infections. At days 7 and 14, these percentages were 6.59% (6/91) and 3.70% (1/27), respectively. The experiments in which mosquitoes became infected after feeding on samples with submicroscopic gametocyte densities typically resulted in low proportions of infected mosquitoes.

Transmission blocking effects per treatment group were quantified as averages of individual level effects; that is, within-person reductions in the proportion of mosquitoes infected at post-

treatment timepoints compared to baseline (Figure 4B, supplementary figures 6 and 7, appendix 1, pp 28-29). All treatment groups showed a statistically significant relative reduction in mosquito infection rates by day 14 (Figure 4B, supplementary tables 15-17, appendix 1, pp 25-27). At earlier time-points, we observed a modest but statistically significant reduction in mosquito infection prevalence on day 2 for DHA-PPQ (20.35%, 95% CI 12.70-27.33, p<0.0001) and for non-ACT-PQ (83.26%, 95% CI 78.11-87.21, p<0.0001) whilst >90% transmission reduction was observed for AL and for ACTs with SLD PQ. For AS-AQ and ACT with SLD TQ, a statistically significant reduction in mosquito infection rates was only observed at day 7, while for SP-AQ and PY-AS, this was only observed by day 14. For these treatment groups, relative differences in infection rates at day 2 ranged from reductions of 2.17% in the SP-AQ arm (95% CI -12.80% -15.14%) to increases in infectivity in the AS-AQ arm ('reduction' of -17.32%, 95% CI -42.92-3.69); neither of these findings were statistically significant. Taken together, AL performed significantly better at reducing mosquito infection rate within 48 hours of treatment, compared to the other ACT regimens DHA-PPQ, PY-AS and AS-AQ at day 2 (p<0.0001 compared to AL) (Figure 5A). The differences in reductions in infectivity became overall smaller at day 7 after treatment (Figure 5B), however, SP-AQ and PY-AS still only showed a <10% reduction, while the reduction in mosquito infection was increased in the DHA-PPQ and AS-AQ groups to 41.51% (95% CI 34.98% - 47.37%) and 55.32% (95% CI 39.21% - 67.16%), respectively

Over all treatment groups, 27 individuals became infectious to mosquitoes after treatment while initially not infecting mosquitoes; 13.92% (11/79) of participants in DHA-PPQ groups, 12.5% (5/40) in SP-AQ groups, 16% (4/25) in the PY-AS group, 10% (2/20) in the AS-AQ group, 1.67% (1/60) in AL groups, 0.72% (1/138) in the ACT plus primaquine groups and 7.5% (3/40) in ACT plus tafenoquine groups. The probability of infecting at least one mosquito was reduced predictably slower than the mosquito infection rate, with only the groups with PQ reaching

>90% reduction in this probability at day 2, followed by AL that achieved >80% reduction at day 7 and ACT-TQ that achieved this at day 14 (supplementary Figure 8, supplementary Tables 18-20, appendix 1 pp 30-33). Relative reductions in oocyst density in dissected mosquitoes preceded the reduction in mosquito infection rates in certain treatment groups, such as DHA-PPQ, SP-AQ, PY-AS and AS-AQ, where a larger reduction in oocyst density was found prior to observing the same level of reduction in mosquito infection rate (supplementary Figure 9, supplementary tables 21-23, appendix 1 pp 34-37).

The clearance of infectivity (i.e. no longer infecting any mosquitoes) preceded the clearance of gametocytes assessed by both microscopy and RT-qPCR (Figure 6). The treatment groups with SLD PQ exhibited the fastest infectivity clearance, followed by those treated with AL (hazard ratios 0.62 (p<0.0001) and 0.66 (p=0.0006) compared to non-ACT-PQ and ACT-PQ, respectively). Infectivity was annulled by day 7 in the AL, ACT-PQ and non-ACT-PQ groups, and by day 14 in the ACT-TQ group, while this effect was slower in the SP-AQ (day 28), DHA-PPQ (day 35) and PY-AS (day 35) groups. Not all infectivity was cleared by the end of follow up (day 28) in the AS-AQ group (4.55 % of individuals still infectious, 95% CI 0.67-30.85). Hazard ratios and between-arm comparisons for the clearance of infectivity, adjusted by baseline PCR gametocyte densities, can be found in supplementary table 24 (appendix 1 p 38). ACT-PQ was significantly faster than all other regimens at gametocyte clearance (p<0.0001 in all comparisons; supplementary tables 25-26, appendix 1 pp 39-40). Gametocytes detectable by microscopy persisted after day 28 in the DHA-PPQ, SP-AQ, PY-AS, AL and non-ACT-PQ groups, while gametocytes were microscopically undetectable by day 14 in the ACT-PQ group and by day 21 in the ACT-TQ group. Gametocytes measured by RT-qPCR (limit of detection of 0.01 gametocytes/µL) persisted in a subset of individuals in all treatment groups until the end of follow-up.

DISCUSSION

This pooled analysis from individual patient data compares the transmission-blocking activity of different regimens of schizonticidal drugs with or without a single low-dose gametocytocide in *P. falciparum* gametocyte carriers in Mali. We found a marked difference between the different ACTs, with AL causing the largest reduction in mosquito infection rate (97.10%) within 48 hours of treatment initiation. The impact of DHA-PPQ, PY-AS and AS-AQ on transmission were significantly less than AL and led to prolonged gametocyte carriage and infectivity post-treatment. Adding a single low-dose of primaquine (0.25 or 0.5 mg/kg) to any ACT accelerated the clearance of gametocytes and led to a significantly greater reduction in mosquito infection rate within 48-hours of treatment.

The effectiveness and utility of the treatments in the six studies analysed here have been discussed in depth in the original trial reports (21–26). This combined analysis represents the first synthesis of this data and direct comparison of these treatments. A number of treatments were tested in multiple studies (DHA-PPQ, DHA-PPQ plus 0.25 mg/kg PQ, AL and SP-AQ) and our results were highly concordant across years (supplementary figure 7, appendix 1, p 29), evidence of the value of established transmission testing facilities and the appropriateness of a pooled analysis. Prior to these trials, there was sparse evidence of the gametocytocidal and transmission reducing efficacy for many of the included treatments. The available data frequently originated from single studies, used disparate and insensitive methodologies for gametocyte quantification, or did not conduct transmission assays to determine the transmissibility of gametocytes (28–32). This was the rationale for including only studies with highly similar enrolment criteria and assessments, including transmission assays before and after initiation of treatment.

This pooled analysis confirms SP-AQ's poor ability to clear gametocytes and reduce transmission, with a significantly lower relative reduction in mosquito infection rate at day 7 compared to DHA-PPQ, AS-AQ, and AL. As the only non-artemisinin-based antimalarial recommended for systematic distribution via seasonal malaria chemoprevention (SMC) (33), SP-AQ's poor performance against gametocytes may reduce the overall community impact of SMC; adding a single low-dose of primaquine to SP-AQ for chemoprevention, would likely improve this.

This pooled analysis provides the first direct comparison of SLD primaquine and SLD tafenoquine with the same partner drug. Our analysis indicates a delayed but highly effective response of SLD tafenoquine compared to SLD primaquine when combined with ACTs, achieving a 99.37% reduction in mosquito infection rate at day 7 from baseline. Although the transmission-blocking efficacy of tafenoquine is dose-dependent, our pooled analysis combined the two highest dose groups (0.83 mg/kg and 1.66 mg/kg) for simplicity, possibly obscuring the effects of the higher dose. Despite these delayed transmission-blocking properties of TQ compared with SLD primaquine in our findings, its long half-life could be a major advantage and could be of relevance to prevent the transmission of drug resistant parasites, which may have an increased gametocyte conversion rate and transmission potential (34,35).

Before ACTs were introduced, several antimalarials including chloroquine and sulfadoxine-pyrimethamine were reported to increase gametocytaemia and/or infectivity after treatment (36,37). Our analysis, almost exclusively examining ACTs, did not find evidence for post-treatment enhancement of infectivity although we did observe that a non-negligible proportion of individuals became infectious after treatment (this proportion being ≥10% of participants in the DHA-PPQ, SP-AQ, PY-AS and AS-AQ groups); this percentage was below 2% in the

remaining treatment groups, including AL. The fact that very few individuals become

gametocyte positive or infectious after AL suggests that, among ACT regimens, AL may be

superior at targeting immature or sequestered gametocytes.

The presence of gametocytes after treatment at densities that normally permit transmission does

not make transmission an inevitability, because gametocytes may be sterilized or become non-

infectious for other reasons before being cleared (12). In this pooled analysis, this discordance

was most pronounced in the AL group and groups with SLD PQ, where post-treatment effects

on infectivity preceded gametocyte clearance. In all other treatment groups, reductions in

gametocyte density and mosquito infection rate followed more similar patterns. The

combination of an ACT with SLD PQ was significantly faster than all other regimens at

gametocyte clearance (100% of microscopical gametocytes by day 14), while ACT-TQ was

the second fastest regimen to clear gametocytes (100% of microscopical gametocytes by day

21). Infectivity clearance was the fastest in the treatment groups with SLD PQ, followed by

AL.

A few limitations in our study warrant consideration. Firstly, we established transmission-

blocking activity in highly infectious individuals. This population allows a detailed assessment

of transmission-blocking properties; however, post-treatment transmission potential is likely

to be smaller in the majority of malaria patients who predominantly have submicroscopic

gametocyte densities or may even be free of gametocytes at clinical presentation. A different

study would be needed to determine the relative importance of sub- vs microscopic gametocyte

carriage for malaria transmission in clinical patients though these would likely require larger

sample sizes for mosquito infectivity endpoints. Secondly, our study utilized direct membrane

feeding assays rather than direct skin feeding, which may have resulted in reduced infectivity,

despite no compelling evidence of gametocytes sequestering in the skin (38). In addition, we

measured oocyst prevalence instead of sporozoite prevalence and some infected mosquitoes

may not have become infectious (39). Nevertheless, comparisons between groups remain valid,

and we observed a strong association between oocyst prevalence and oocyst densities,

indicating that a higher proportion of infected mosquitoes reflects a greater transmission

potential. Lastly, this pooled analysis set out to assess the ability of antimalarial treatment to

prevent the transmission of drug-resistant parasites. Considering that gametocytes in

PfKelch13 mutant infections might preferentially survive artemisinin exposure and infect

mosquitoes (35), our findings regarding ACTs may not be generalisable to areas where

artemisinin partial resistance is present. In addition, increased gametocytaemia was found to

be an early indicator of resistance emergence against previous non-ACT first-line treatments

(34). Consequently, while our results indicate that AL is nearly as effective as ACT-PQ in

reducing mosquito infection rates, it remains unclear whether this would extend to settings with

artemisinin-resistant malaria infections. Our data on SLD gametocytocides in combination

with ACTs therefore supports the 2023 advice from the WHO malaria policy and advisory

group to expand the focus on reducing parasite transmission with SLD PQ in areas where

partial artemisinin resistance has been detected (20). Additionally, we observed high

transmission-blocking efficacy of AL when administered as a directly observed therapy (DOT);

its efficacy may be lower in real-life settings where treatment adherence may be lower.

In conclusion, utilizing individual patient-level data from six clinical trials conducted at the

same study site with highly consistent transmission experiments across trials, we showed

pronounced differences in anti-gametocyte and anti-transmission effects between ACTs, with

AL showing the most effectiveness in blocking transmission. Additionally, our findings

confirm the rapid effects of SLD PQ in clearing and sterilizing gametocytes when used in

combination with an ACT, while the addition of an SLD TQ to ACTs has a delayed

transmission-blocking effect compared to SLD PQ. Lastly, our analysis confirms considerably

higher post-treatment transmission after SP-AQ compared to most ACTs, and adding an SLD PQ to SP-AQ may be beneficial to block malaria transmission in community treatment campaigns.

Data Availability Statement

All trial data are available through a novel open-access clinical epidemiology database resource, ClinEpiDB; and code for analysis and the selection of data used for this analysis can be found on https://github.com/leenvh/NECTAR-pooled-analysis.

Funding

The original studies were supported by the Bill & Melinda Gates Foundation (OPP1013179, OPP1089413, INV-002098, INV-005735); LNV is further supported by a Biotechnology and Biological Sciences Research Council LIDo Ph.D. studentship (BB/T008709/1). WS is supported by a Wellcome Trust fellowship (218676/Z/19/Z/WT) and Jordache Ramjith and Teun Bousema by a VICI fellowship from the Dutch Research Council (NWO; grant number 09150182210039).

Competing interests

The authors have declared that no competing interests exist

Acknowledgements

We would like to thank everyone involved in the original studies, including the local safety monitor, members of the data safety and monitoring board, and all MRTC study staff for their

assistance and support. Finally, we are thankful to all study participants and the population of

Ouélessébougou, Mali, for their cooperation.

Author contributions

LNV, JR, AM, CD, AD, WS and TB conceived the study. AM, MJS, MER, LNV, KS, YS,

SMN, MD, SM, SK, SS, AY, HD, SFT, RG, JMB, CD, AD, WS and TB conceived and

undertook individual studies. KL performed molecular analyses. JR, LNV, AM, RG, JMB, CD,

AD, WS and TB analysed the data and interpreted results. LNV, JR, WS and TB wrote the first

draft of the manuscript. All authors reviewed and edited the manuscript and read and approved

the final manuscript.

TABLES

 Table 1. Overview of the included studies. Rows in grey indicate treatment groups that
 were not included in the analyses.

Study	Year	Treatment group	Number of participants	Treatment category	Study population	Reference
PQ01	2013-2014	DHA-PPQ	16	DHA-PPQ	G6PD+ males, 5-50 years, ≥32 gametocytes/µL	(24)
		DHA-PPQ + 0.0625 mg/kg PQ	16	/		
		DHA-PPQ + 0.125 mg/kg PQ	17	/		
		DHA-PPQ + 0.25 mg/kg PQ	15	ACT-PQ		
		DHA-PPQ + 0.5 mg/kg PQ	17	ACT-PQ		
PQ03	2016	SP-AQ	20	SP-AQ	G6PD+ males, 5-50 years, asymptomatic, ≥16 gametocytes/µL	(23)
		SP-AQ + 0.25 mg/kg PQ	20	Non-ACT-PQ		
		DHA-PPQ	20	DHA-PPQ		
		DHA-PPQ + MB	20	/		
NECTAR1	2019	DHA-PPQ	25	DHA-PPQ	Males and non-pregnant females, 5-50 years, asymptomatic, ≥16 gametocytes/µL	(25)
		DHA-PPQ + 0.25 mg/kg PQ	25	ACT-PQ		
		PY-AS	25	PY-AS		
		PY-AS + 0.25 mg/kg PQ	25	ACT-PQ		
NECTAR2	2020	DHA-PPQ	20	DHA-PPQ	G6PD+ males and non-pregnant females, 12-50 years, asymptomatic, ≥16 gametocytes/µL	(22)
		DHA-PPQ + 0.42 mg/kg TQ	20	/		
		DHA-PPQ + 0.83 mg/kg TQ	20	ACT-TQ		
		DHA-PPQ + 1.66 mg/kg TQ	20	ACT-TQ		
NECTAR3	2021	AL	20	AL	G6PD+ males and non-pregnant females, 10-50 years, asymptomatic, ≥16 gametocytes/µL	(21)
		AL + 0.25 mg/kg PQ	20	ACT-PQ		
		SP-AQ	20	SP-AQ		
		SP-AQ + 1.66 mg/kg TQ	20	/		
NECTAR4	2022	AL	20	AL	Males and non-pregnant females, 10-50 years, asymptomatic, ≥16 gametocytes/µL	(26)
		AL-AQ	20	AL		
		AL-AQ + 0.25 mg/kg PQ	20	ACT-PQ		
		AS-AQ	20	AS-AQ		
		AS-AQ + 0.25 mg/kg PQ	20	ACT-PQ		

 FIGURE LEGENDS

 Figure 1. Study design of included trials. All studies assessed infectivity to mosquitoes
 before (d0), during (d2) and one and two weeks after initiation of treatment (d7 and d14) with
 additional time-points that differed between studies. Tick marks represent days; circles
 indicate sampling/screening time points. Circles that are encompassed by larger red circles
 indicate that a standard dose schizonticide was administered at these study visits, while a
 single low-dose gametocytocide was administered at the time points with a larger blue circle.
 Grey coloured circles indicate that parasite densities were assessed by both microscopy
 (asexual parasite and gametocyte densities) and RT-qPCR (gametocyte densities). At other
 study visits, parasite densities were determined by microscopy only (white circles) or RT-
 qPCR only (dark grey circles). Mosquito infectivity assays were conducted at the study visits
 marked with a black mosquito symbol, while a grey mosquito symbol indicates that mosquito
 infectivity assays were only conducted at that time point if any of the previous two assays
 resulted in at least one infected mosquito.

 Figure 2. Baseline study characteristics. **A.** Violin plot of microscopical asexual parasite
 density (parasites/µL) distribution per study. **B.** Violin plot of microscopical gametocyte
 density (gametocytes/µL) distribution per study. **C**. The mean proportion of mosquitoes that
 became infected after feeding on venous blood collected at enrolment, prior to treatment, per
 study. Vertical bars represent 95% CIs estimated from a logistic regression model. **D**. Results
 from a logistic regression between microscopically determined gametocyte densities
 (gametocytes / µL) on a log10 scale and the proportion of infected mosquitoes over the
 different study years shown by the different colours. Mosquito feeding assays in this analysis
 were conducted before treatment was initiated. The black line indicates the overall trend
 averaged across all years with the shaded area showing the 95% confidence interval for this
 overall fit. Visualisations represent a total of 422 observations, from 42 (2013-2014), 60
 (2016), 100 (2019), 60 (2020), 60 (2021) and 100 (2022) study participants. The median
 number of dissected mosquitoes per study participant (panel C) was 71.8 (IQR 65.6-77) for
 2013-2014, 79 (IQR 72-84) for 2016, 64 (IQR 57-70) for 2019, 60 (IQR 51.8-66.5) for 2020,
 62 (IQR 53.8-64.2) for 2021 and 61 (IQR 55-66) for 2022.

 Figure 3. Gametocyte prevalence and densities. **A.** scatter plot of the association between
 gametocyte density measured by microscopy (x-axis) and RT-qPCR (y-axis) pre-treatment,
 both on a log10 scale. A linear model with an interaction by year was used to estimate the
 study specific trend lines (shown in colour with estimated slopes (β) indicated in the legend).
 A linear mixed effects model was used to estimate the trend line averaged across the study
 years (β=0.94) shown by the black line, and the corresponding 95% CI, shown by the grey
 shaded area. The dashed line represents the line of equality where measurements by
 microscopy and PCR would be equal. **B-D.** Bar charts illustrating the relative reduction
 compared to baseline in gametocyte prevalence by microscopy (**B**), and gametocyte densities
 measured by microscopy (**C**) and molecular methods (**D**), by treatment arm over three time
 points (Day 2 - indigo, Day 7 - turquoise, and Day 14 - green). Vertical bars depict the 95%
 confidence intervals for these estimates. Due to inflated standard errors the y-axis was cut off
 below -50. Visualisations represent data from 422 individuals at baseline (79, 40, 25, 20, 60,
 20, 138 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, non-ACT-PQ,
 ACT-PQ and ACT-TQ groups, respectively). At day 2, 369 individuals were included (65,
 39, 23, 20, 58, 19, 105 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL,
 Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). Data from 357 individuals at

day 7 is shown (57, 38, 24, 20, 57, 19, 104 and 38 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). Day 14 includes data from 357 individuals (60, 38, 24, 19, 57, 18, 105 and 36 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively).

Figure 4. Infectivity of submicroscopic gametocyte infections and the relative reduction in the proportion of infected mosquitoes compared to baseline per treatment category. **A**. Stacked bar chart representing the number of observations for each proportion of infected mosquitoes (rounded to the nearest integer) at baseline and at days 2,7 and 14 post-treatment initiation. For each day of follow-up, individual study participants contribute a single observation. Bars are coloured by the presence of gametocytes by microscopy (blue) or by PCR only (orange). Baseline visualisations represent a total of 422 study participants; per study 42 (2013-2014), 60 (2016), 100 (2019), 60 (2020), 60 (2021) and 100 (2022) participants were enrolled and presented here. At day 2, data from 375 individuals are presented (60, 99, 60, 58, 98 participants from the 2016, 2019, 2020, 2021 and 2022 studies, respectively). At day 7 post-treatment initiation, 367 participants are presented (56, 98, 59, 58 and 97 participants from the 2016, 2019, 2020, 2021 and 2022 studies, respectively). Finally, at day 14, data from 218 individuals are presented (47, 56, 17 and 96 participants from the 2019, 2020, 2021 and 2022 studies, respectively). **B.** Bar chart illustrating the relative reduction compared to baseline in the proportion of infected mosquitoes by treatment arm over three time points (Day 2 - indigo, Day 7 - turquoise, and Day 14 - green). Vertical bars depict the 95% confidence intervals for these estimates. Visualisations represent data from 416 individuals at baseline (79, 40, 25, 20, 60, 20, 139 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). At day 2, 416 individuals were included (78, 40, 25, 20, 58, 20, 135 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). Data from 409 individuals at day 7 is shown (76, 39, 25, 20, 57, 19, 134 and 39 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups, respectively). Day 14 includes data from 218 individuals (43, 15, 25, 19, 39, 40 and 37 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, ACT-PQ and ACT-TQ groups, respectively).

Figure 5. Between-group comparison of the reduction in proportion infected mosquitoes at days 2 and 7 post-treatment, compared to baseline. Heatmaps representing the percentage reduction in the proportion infection mosquitoes per treatment category at day 2 (**A**) and day 7 (**B**) compared to baseline in the top cells, with 95% confidence intervals and p-value comparing to baseline. Other cells in the heatmap represent the p-values comparing treatment groups. Heatmap cells are coloured by the absolute difference between treatment groups in the relative reduction in proportion infected mosquitoes at days 2 and 7 post-treatment, compared to baseline. For example, DHA-PPQ achieves 20.35% reduction in the proportion of infected mosquitoes by day 2 compared to 97.10% for AL; the difference between these arms (76.75% lower reduction for DHA-PPQ) is statistically significant (p<0.0001).

Figure 6. Time to clearance of infectivity and gametocytes per treatment category. Kaplan-Meier survival curves showing the cumulative probability of remaining uncleared of gametocytes detected by microscopy (purple), gametocytes detected by PCR (turquoise) and infectivity to mosquitos (green) over time stratified across different antimalarial treatment

categories (DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ, ACT-TQ).
Shaded areas indicate 95% confidence intervals for the Kaplan-Meier survival estimates.
Survival curves showing infectivity represent data from 417 individuals (79, 40, 25, 20, 58,
20, 135 and 40 individuals from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ,
ACT-PQ and ACT-TQ groups, respectively). Survival curves visualising gametocytes by
microscopy show data from 375 individuals (65, 40, 25, 20, 58, 20, 107 and 40 individuals
from the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ
groups, respectively) and 417 individuals (79, 40, 25, 20, 58, 20, 135 and 40 individuals from
the DHA-PPQ, SP-AQ, PY-AS, AS-AQ, AL, Non-ACT-PQ, ACT-PQ and ACT-TQ groups,
respectively) for gametocyte assessment by RT-qPCR.
598

REFERENCES

600   1.   White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents
601   Chemother. 1997 Jul;41(7):1413–22.

602   2.   Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG, et al. Quantitative assessment of
603   Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.
604   Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):E1214-1223.

605   3.   Bousema T, Drakeley C. Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax
606   Gametocytes in Relation to Malaria Control and Elimination. Clin Microbiol Rev. 2011 Apr;24(2):377–410.

607   4.   Stepniewska K, Humphreys GS, Gonçalves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of Single-Dose
608   Primaquine With Artemisinin Combination Therapy on Plasmodium *falciparum* Gametocytes and Transmission:
609   An Individual Patient Meta-Analysis. The Journal of Infectious Diseases. 2022 Apr 1;225(7):1215–26.

610   5.   Bolscher JM, Koolen KMJ, Van Gemert GJ, Van De Vegte-Bolmer MG, Bousema T, Leroy D, et al. A
611   combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct
612   dynamics of marketed and experimental drugs. Journal of Antimicrobial Chemotherapy. 2015 May
613   1;70(5):1357–66.

614   6.   Lelièvre J, Almela MJ, Lozano S, Miguel C, Franco V, Leroy D, et al. Activity of Clinically Relevant
615   Antimalarial Drugs on Plasmodium falciparum Mature Gametocytes in an ATP Bioluminescence "Transmission
616   Blocking" Assay. Waller RF, editor. PLoS ONE. 2012 Apr 13;7(4):e35019.

617   7.   van Pelt-Koops JC, Pett HE, Graumans W, van der Vegte-Bolmer M, van Gemert GJ, Rottmann M, et al. The
618   Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium
619   falciparum Transmission to Anopheles Mosquito Vector. Antimicrob Agents Chemother. 2012 Jul;56(7):3544–8.

620   8.   Chavalitshewinkoon-Petmitr P, Pongvilairat G, Auparakkitanon S, Wilairat P. Gametocytocidal activity of
621   pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
622   Parasitology International. 2000 Feb;48(4):275–80.

623   9.   Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ, et al. Male and Female
624   Plasmodium falciparum Mature Gametocytes Show Different Responses to Antimalarial Drugs. Antimicrob
625   Agents Chemother. 2013 Jul;57(7):3268–74.

626   10.   Schneider P, Bousema JT, Gouagna LC, Otieno S, van de Vegte-Bolmer M, Omar SA, et al. Submicroscopic
627   Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg. 2007
628   Mar;76(3):470–4.

629   11.   Butcher GA. Development of malaria blood-stage vaccines: learning from mosquitoes. Transactions of the Royal
630   Society of Tropical Medicine and Hygiene. 2007 Jun;101(6):530–1.

631   12.   Bradley J, Soumaré HM, Mahamar A, Diawara H, Roh M, Delves M, et al. Transmission-blocking Effects of
632   Primaquine and Methylene Blue Suggest Plasmodium falciparum Gametocyte Sterilization Rather Than Effects
633   on Sex Ratio. Clinical Infectious Diseases. 2019 Sep 27;69(8):1436–9.

634   13.   White NJ, Ashley EA, Recht J, Delves MJ, Ruecker A, Smithuis FM, et al. Assessment of therapeutic responses
635   to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J. 2014 Dec 9;13:483.

636   14.   Rosenthal PJ, Asua V, Bailey JA, Conrad MD, Ishengoma DS, Kamya MR, et al. The emergence of artemisinin
637   partial resistance in Africa: how do we respond? The Lancet Infectious Diseases. 2024
638   Mar;S1473309924001415.

639   15.   Nguyen TD, Gao B, Amaratunga C, Dhorda M, Tran TNA, White NJ, et al. Preventing antimalarial drug
640   resistance with triple artemisinin-based combination therapies. Nat Commun. 2023 Jul 29;(1):4568.

641   16.   Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, et al. Optimum population-level use of
642   artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015 Dec;3(12):e758-766.

17. World Health Organization. World malaria report 2023 [Internet]. World Health Organization; 2023 [cited 2023
Dec 11]. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-
2022

18. Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus
Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria. N Engl J Med. 2019 Jan 17;380(3):229–41.

19. World Health Organization. Global Malaria Programme: WHO policy brief on single-dose primaquine as
gametocytocide in Plasmodium falciparum malaria. 2015.

20. World Health Organization. WHO Malaria Policy Advisory Group (MPAG) meeting report [Internet]. 2023
[cited 2023 Nov 15]. Available from: https://iris.who.int/bitstream/handle/10665/368391/9789240074385-
eng.pdf?sequence=1

21. Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, Sacko A, et al. Artemether–lumefantrine with or
without single-dose primaquine and sulfadoxine–pyrimethamine plus amodiaquine with or without single-dose
tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in
Ouelessebougou, Mali. The Lancet Microbe. 2024 Jul;5(7):633–44.

22. Stone W, Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, et al. Single low-dose tafenoquine
combined with dihydroartemisinin–piperaquine to reduce Plasmodium falciparum transmission in
Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. The Lancet Microbe. 2022
May;3(5):e336–47.

23. Dicko A, Roh ME, Diawara H, Mahamar A, Harouna M. Soumare, Lanke K, et al. Efficacy and safety of
primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-
blind, randomised controlled trial. Lancet Infect Dis. 2018 Jun;18(6):627–39.

24. Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, et al. Primaquine to reduce transmission of
Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet
Infect Dis. 2016 Jun;16(6):674–84.

25. Stone W, Mahamar A, Sanogo K, Sinaba Y, Niambele SM, Sacko A, et al. Pyronaridine–artesunate or
dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum
malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial. The Lancet
Microbe. 2022 Jan;3(1):e41–51.

26. Mahamar A, Vanheer LN, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, et al. Artemether-lumefantrine-
amodiaquine or artesunate-amodiaquine combined with single low-dose primaquine to reduce Plasmodium
falciparum malaria transmission in Ouélessébougou, Mali: a five-arm, phase 2, single-blind, randomised clinical
trial. MedRXiv. 2024;

27. Ouédraogo AL, Guelbéogo WM, Cohuet A, Morlais I, King JG, Gonçalves BP, et al. A protocol for membrane
feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles
gambiae. 2013;4(16):4.

28. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for
clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a
randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014 Feb;14(2):130–9.

29. Okebe J, Bousema T, Affara M, DiTanna G, Eziefula AC, Jawara M, et al. The gametocytocidal efficacy of
primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia
(PRINOGAM): study protocol for a randomised controlled trial. Trials. 2015 Mar 1;16:70.

30. Gonçalves BP, Tiono AB, Ouédraogo A, Guelbéogo WM, Bradley J, Nebie I, et al. Single low dose primaquine
to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children
with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med [Internet]. 2016
Mar 8 [cited 2021 Jun 12];14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782330/

31. Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of
primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated
Plasmodium falciparum malaria in Tanzania. Malar J. 2016 Jun 10;15:316.

32. Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gonçalves BP, et al. Safety of single low-dose
primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label,
randomized, safety trials. PLoS One. 2018;13(1):e0190272.

33. World Health Organization. Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus
amodiaquine in children: a field guide, second edition. 2023.

34. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, et al. Increased Gametocytemia after
Treatment: An Early Parasitological Indicator of Emerging Sulfadoxine-Pyrimethamine Resistance in
Falciparum Malaria. J INFECT DIS. 2008 Jun;197(11):1605–13.

35. Witmer K, Dahalan FA, Delves MJ, Yahiya S, Watson OJ, Straschil U, et al. Transmission of Artemisinin-
Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. Antimicrobial Agents and
Chemotherapy. 2020 Dec 16;65(1):e00898-20.

36. Sokhna CS, Trape JF, Robert V. Gametocytaemia in senegalese children with uncomplicated Falciparum malaria
treated with chloroquine, amodiaquine or sulfadoxine + pyrimethamine. Parasite. 2001 Sep 1;8(3):243–50.

37. Enosse S, Butcher GA, Margos G, Mendoza J, Sinden RE, Høgh B. The mosquito transmission of malaria: the
effects of atovaquone-proguanil (Malarone™) and chloroquine. Transactions of the Royal Society of Tropical
Medicine and Hygiene. 2000 Jan;94(1):77–82.

38. Meibalan E, Barry A, Gibbins MP, Awandu S, Meerstein-Kessel L, Achcar F, et al. Plasmodium falciparum
Gametocyte Density and Infectivity in Peripheral Blood and Skin Tissue of Naturally Infected Parasite Carriers
in Burkina Faso. J Infect Dis. 2019 Dec 26;223(10):1822–30.

39. Stone WJR, Eldering M, Van Gemert GJ, Lanke KHW, Grignard L, Van De Vegte-Bolmer MG, et al. The
relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays. Sci Rep. 2013 Dec
4;3(1):3418.

713
714

Figure 1.

Figure 2.

722 Figure 3.

723
724
725

726   Figure 4.

727
728
729

730   Figure 5.

A

B

731
732
733

Figure 6.